Drug updated on 10/29/2024
| Dosage Form | Tablet (oral; 10 mg) |
| Drug Class | Potassium channel blockers |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older.
Latest News
Summary
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- Treatment with 3,4-DAP resulted in a significant improvement in Quantitative Myasthenia Gravis (QMG) scores, with a decrease of 2.76 points (95% CI: -4.08 to -1.45).
- Compound Muscle Action Potential (CMAP) amplitude significantly improved in patients with Lambert-Eaton myasthenic syndrome (LEMS) treated with 3,4-DAP, with a mean difference of 1.34 mV (95% CI: 0.98 to 1.70).
- There is no safety information available in the reviewed studies.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Firdapse (amifampridine) Prescribing Information. | 2024 | Catalyst Pharmaceuticals, Inc., Coral Gables, FL |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| 3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials | 2021 | BMC Neurology |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Guideline for the management of myasthenic syndromes. | 2023 | Therapeutic Advances in Neurological Disorders |
| Update in the management of myasthenia gravis and lambert-eaton myasthenic syndrome. | 2021 | Neurologic Clinics |